KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBIT (2017 - 2025)

Historic EBIT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$46.7 million.

  • Biomarin Pharmaceutical's EBIT fell 14099.64% to -$46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 7581.25%. This contributed to the annual value of $484.2 million for FY2024, which is 16064.68% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EBIT of -$46.7 million as of Q3 2025, which was down 14099.64% from $276.9 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's EBIT ranged from a high of $276.9 million in Q2 2025 and a low of -$65.9 million during Q4 2021
  • Moreover, its 5-year median value for EBIT was $39.2 million (2022), whereas its average is $63.3 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's EBIT surged by 136292.93% in 2023, and later tumbled by 14099.64% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's EBIT stood at -$65.9 million in 2021, then surged by 80.13% to -$13.1 million in 2022, then soared by 308.43% to $27.3 million in 2023, then skyrocketed by 491.69% to $161.4 million in 2024, then tumbled by 128.93% to -$46.7 million in 2025.
  • Its EBIT stands at -$46.7 million for Q3 2025, versus $276.9 million for Q2 2025 and $223.9 million for Q1 2025.